A Phase I study of WT4869 in patients with advanced solid malignancies

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221527

Enrollment

Registered

2011-07-29

Start date

2011-08-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid malignancies

Interventions

investigational material(s) Generic name etc : WT4869 INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Histologically or cytologically confirmed solid malignancies - HLA-A*2402 - Advanced cancer patient who is refractory to standard therapy or no established treatment exists

Exclusion criteria

Exclusion criteria: - Concomitant infection requiring systemic administration of antibiotics or antiviral drugs - Positive for either HIV antibody, HBs antigen or HCV antibody testing within 90 days before entry - Brain metastasis which is symptomatic or requiring treatment, excluding primary malignant brain tumor

Design outcomes

Primary

Measure	Time frame
safety Safety CTCAE ver4.0	—

Secondary

Measure	Time frame
efficacy Tumor response, Biomarkers Tumor response: RECIST Biomarkers: DTH, CTL induction, anti WT1 antibody etc	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026